January 4, 2018 / 1:49 PM / 5 months ago

BRIEF-Lycera Corp Announces Initiation Of Phase 1b Study Of Novel Immuno-Oncology Candidate LYC-55716 In Combination With Pembrolizumab

Jan 4 (Reuters) - Merck & Co Inc:

* LYCERA CORP ANNOUNCES INITIATION OF PHASE 1B STUDY OF NOVEL IMMUNO-ONCOLOGY CANDIDATE LYC-55716 IN COMBINATION WITH PEMBROLIZUMAB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below